Trevi Therapeutics, Inc. (TRVI) closed at $6.41, with a 3.9% gain over the last four weeks. Wall Street analysts set a mean price target of $21.22, indicating a potential upside of 231.1%. The targets range from $13.00 to $29.00, with a standard deviation of $4.92.
Over the past month, the Zacks Consensus Estimate for TRVI’s current year earnings has increased by 3.2%, with no negative revisions reported. TRVI currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 stocks ranked based on earnings estimate factors.
